Posted by Michael Wonder on 30 Jul 2017
Roche leukaemia drug gets FDA breakthrough therapy designation
28 July 2017 - Roche Holding AG's Venclexta has won breakthrough therapy designation in acute myeloid leukaemia from the U.S. FDA, the Swiss drug maker said on Friday.
The designation covers Venclexta in combination with low dose cytarabine for elderly patients with previously untreated acute myeloid leukaemia who are ineligible for intensive chemotherapy, it said.
Venclexta is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Roche unit Genentech in the United States and by AbbVie elsewhere.
